β-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials.
To more precisely quantify the effect of barley β-glucan on blood lipid concentrations in humans and to examine the factors that could affect its efficacy. Eleven eligible randomized clinical trials published from 1989 to 2008 were identified from nine databases. Weighted mean effect sizes were calculated for net differences in lipid profile using a random effect model (RevMan 4.2). Overall, barley and β-glucan isolated from barley lowered total and low-density lipoprotein (LDL) cholesterol concentrations by 0.30 mmol/l (95% confidence interval (CI): -0.39 to -0.21, P<0.00001) and 0.27 mmol/l (95% CI: -0.34 to -0.20, P<0.00001), respectively, compared with control. The pattern of cholesterol-lowering action of barley in this analysis could not be viewed as a dose-dependent response. There were no significant subgroup differences by type of intervention and food matrix. Increased consumption of barely products should be considered as a dietary approach to reduce LDL cholesterol concentrations.